USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$9.03M
Market Cap
-
P/E Ratio
-2.3
EPS
$5.01
52 Week High
$1.41
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $1.5M |
Total Revenue | $1.5M |
Cost Of Revenue | $22K |
Costof Goods And Services Sold | $22K |
Operating Income | -$14M |
Selling General And Administrative | $6.5M |
Research And Development | $9.4M |
Operating Expenses | $16M |
Investment Income Net | - |
Net Interest Income | $1.3M |
Interest Income | $1.3M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $22K |
Income Before Tax | -$13M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | -$13M |
Ebitda | -$13M |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Total Assets | $24M |
Total Current Assets | $24M |
Cash And Cash Equivalents At Carrying Value | $23M |
Cash And Short Term Investments | $23M |
Inventory | - |
Current Net Receivables | - |
Total Non Current Assets | $403K |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $726K |
Other Non Current Assets | - |
Total Liabilities | $4.7M |
Total Current Liabilities | $3.4M |
Current Accounts Payable | $1.4M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | - |
Total Non Current Liabilities | $1.3M |
Capital Lease Obligations | - |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | - |
Other Current Liabilities | $2M |
Other Non Current Liabilities | - |
Total Shareholder Equity | $19M |
Treasury Stock | - |
Retained Earnings | -$321M |
Common Stock | $5.5K |
Common Stock Shares Outstanding | $5.5M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$14M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $22K |
Capital Expenditures | $15K |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$15K |
Cashflow From Financing | $15M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$13M |
Field | Value (USD) |
---|---|
Gross Profit | $1.5M |
Total Revenue | $1.5M |
Cost Of Revenue | $22K |
Costof Goods And Services Sold | $22K |
Operating Income | -$14M |
Selling General And Administrative | $6.5M |
Research And Development | $9.4M |
Operating Expenses | $16M |
Investment Income Net | - |
Net Interest Income | $1.3M |
Interest Income | $1.3M |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $22K |
Income Before Tax | -$13M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$13M |
Comprehensive Income Net Of Tax | - |
Ebit | -$13M |
Ebitda | -$13M |
Net Income | -$13M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.